Abstract
Purpose
To evaluate semi-automated measurement of liver surface nodularity (LSN) on MDCT in a cause-specific cohort of patients with chronic hepatitis C virus infection (HCV) for identification of hepatic fibrosis (stages F0–4).
Methods
MDCT scans in patients with known HCV were evaluated with an independently validated, semi-automated LSN measurement tool. Consecutive LSN measurements along the anterior liver surface were performed to derive mean LSN scores. Scores were compared with METAVIR fibrosis stage (F0–4). Fibrosis stages F0–3 were based on biopsy results within 1 year of CT. Most patients with cirrhosis (F4) also had biopsy within 1 year; the remaining cases had unequivocal clinical/imaging evidence of cirrhosis and biopsy was not indicated.
Results
288 patients (79F/209M; mean age, 49.7 years) with known HCV were stratified based on METAVIR fibrosis stage: F0 (n = 43), F1 (n = 29), F2 (n = 53), F3 (n = 37), and F4 (n = 126). LSN scores increased with increasing fibrosis (mean: F0 = 2.3 ± 0.2, F1 = 2.4 ± 0.3, F2 = 2.6 ± 0.5, F3 = 2.9 ± 0.6, F4 = 3.8 ± 1.0; p < 0.001). For identification of significant fibrosis (≥ F2), advanced fibrosis (≥ F3), and cirrhosis (≥ F4), the ROC AUCs were 0.88, 0.89, and 0.90, respectively. The sensitivity and specificity for significant fibrosis (≥ F2) using LSN threshold of 2.80 were 0.68 and 0.97; for advanced fibrosis (≥ F3; threshold = 2.77) were 0.83 and 0.85; and for cirrhosis (≥ F4, LSN threshold = 2.9) were 0.90 and 0.80.
Conclusion
Liver surface nodularity assessment at MDCT allows for accurate discrimination of intermediate stages of hepatic fibrosis in a cause-specific cohort of patients with HCV, particularly at more advanced levels.
Similar content being viewed by others
References
Freiman JM, Tran TM, Schumacher SG, et al. (2016) Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med 165:345–355
WHO (2017) Hepatitis C virus fact sheet. Accessed 17 May 2017
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57
Nuno Solinis R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y (2016) Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence. Infect Dis Ther 5:491–508
Friedrich-Rust M, Nierhoff J, Lupsor M, et al. (2012) Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 19:E212–E219
Friedrich-Rust M, Ong M-F, Martens S, et al. (2008) Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134:960–974
Singh S, Venkatesh SK, Wang Z, et al. (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13:440–451
Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM (2007) Utrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 5:1214–1220
Wang Q-B, Zhu H, Liu H-L, Zhang B (2012) Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology 56:239–247
Castera L, Vergniol J, Foucher J, et al. (2005) Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128:343–350
Foucher J, Chanteloup E, Vergniol J, et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55:403–408
Yin M, Glaser KJ, Talwalkar JA, et al. (2016) Hepatic MR elastography: clinical performance in a series of 1377 consecutive examinations. Radiology 278:114–124
Tang A, Cloutier G, Szeverenyi NM, Sirlin CB (2015) Ultrasound elastography and MR elastography for assessing liver fibrosis: part 2, diagnostic performance, confounders, and future directions. Am J Roentgenol 205:33–40
Wagner M, Corcuera-Solano I, Lo G, et al. (2017) Technical failure of MR elastography examinations of the liver: experience from a large single-center study. Radiology. https://doi.org/10.1148/radiol.2016160863:160863
Petitclerc L, Sebastiani G, Gilbert G, Cloutier G, Tang A (2016) Liver fibrosis: review of current imaging and MRI quantification techniques. J Magn Reson Imaging. https://doi.org/10.1002/jmri.25550
Furusato Hunt OM, Lubner MG, Ziemlewicz TJ, Munoz Del Rio A, Pickhardt PJ (2016) The liver segmental volume ratio for noninvasive detection of cirrhosis: comparison with established linear and volumetric measures. J Comput Assist Tomogr 40:478–484
Honda H, Onitsuka H, Masuda K, et al. (1990) Chronic liver disease: value of volumetry of liver and spleen with computed tomography. Radiat Med 8:222–226
Smith AD, Branch CR, Zand K, et al. (2016) Liver surface nodularity quantification from routine CT images as a biomarker for detection and evaluation of cirrhosis. Radiology 280:771–781
Zhou X, Lu T, Wei Y, Chen X (2007) Liver volume variation in patients with virus-induced cirrhosis: findings on MDCT. AJR 189:W153–W159
Smith AD, Zand KA, Florez E, et al. (2016) Liver surface nodularity score allows prediction of cirrhosis decompensation and death. Radiology. https://doi.org/10.1148/radiol.2016160799:160799
Pickhardt PJ, Malecki K, Hunt OF, et al. (2017) Hepatosplenic volumetric assessment at MDCT for staging liver fibrosis. Eur Radiol 27:3060–3068
Pickhardt PJ, Malecki K, Kloke J, Lubner MG (2016) Accuracy of liver surface nodularity quantification on MDCT as a noninvasive biomarker for staging hepatic fibrosis. AJR 207:1194–1199
Lo GC, Besa C, King MJ, et al. (2017) Feasibility and reproducibility of liver surface nodularity quantification for the assessment of liver cirrhosis using CT and MRI. Eur J Radiol Open 4:95–100
Smith AD, Branch CR, Zand K, et al. (2016) Liver surface nodularity quantification from routine computed tomography images as a biomarker for detection and evaluation of cirrhosis. Radiology 280:771–781
Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 24:289–293
Martinez SM, Crespo G, Navasa M, Forns X (2011) Noninvasive assessment of liver fibrosis. Hepatology 53:325–335
Daginawala N, Li B, Buch K, et al. (2016) Using texture analyses of contrast enhanced CT to assess hepatic fibrosis. Eur J Radiol 85:511–517
Lubner MG, Malecki K, Kloke J, Ganeshan B, Pickhardt PJ (2017) Texture analysis of the liver at MDCT for assessing hepatic fibrosis. Abdom Radiol 42:2069–2078
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding supported this work.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The need for informed consent was waived.
Disclosures
MGL: Grant funding—Philips, Ethicon. PJP: Co-founder, VirtuoCTC, Advisor to Check-Cap, Shareholder in Cellectar, Elucent, SHINE and for other authors there are no relevant disclosures.
Rights and permissions
About this article
Cite this article
Lubner, M.G., Jones, D., Said, A. et al. Accuracy of liver surface nodularity quantification on MDCT for staging hepatic fibrosis in patients with hepatitis C virus. Abdom Radiol 43, 2980–2986 (2018). https://doi.org/10.1007/s00261-018-1572-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-018-1572-6